Suppr超能文献

STAT3 基因靶向敲除的巨噬细胞增强 CD8 T 细胞交叉呈递

Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.

机构信息

Department of Immunology and Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, United States.

出版信息

Immunol Lett. 2010 Jul 8;131(2):126-30. doi: 10.1016/j.imlet.2010.03.004. Epub 2010 Mar 25.

Abstract

CD8 T cell tolerance, once thought to be largely a result of clonal deletion, is now appreciated to be much more complex, additionally involving multiple permutations of partial loss of effector function in residual clonal populations. This is especially important in the context of tumor immunity, in which persistent tolerized cytotoxic CD8 T cells (CTL), if reactivated, could potentially mount a protective response. Previously we have shown that antigen-presenting cells (APCs) with a targeted disruption of STAT3 break tolerance in CD4 T cells. Here we evaluate the STAT3-defective APC in terms of its ability to induce a productive CTL response. Our data demonstrate that macrophages derived from conditional STAT3 knockout mice are superior to wild-type macrophages in terms of their ability to prime cognate CTL responses, and to cross-present tumor-derived antigen to CTLs in vitro. CTLs cultured with STAT3-deficient APCs demonstrated a stronger proliferative response and produced increased amounts of IFN-gamma and TNF-alpha, all of which have been shown to be diminished in tumor-tolerized CD8 T cells. Targeting STAT3 signaling represents therefore an enticing strategy to augment CTL responses in the tumor-bearing host.

摘要

CD8 T 细胞耐受,曾经被认为主要是由于克隆删除的结果,现在被认为要复杂得多,此外还涉及到残留克隆群体中效应功能部分丧失的多种排列。这在肿瘤免疫的背景下尤为重要,其中持续耐受的细胞毒性 CD8 T 细胞(CTL)如果被重新激活,可能会产生保护性反应。此前我们已经表明,STAT3 靶向敲除的抗原呈递细胞(APC)可打破 CD4 T 细胞的耐受。在这里,我们评估了 STAT3 缺陷型 APC 在诱导有效 CTL 反应方面的能力。我们的数据表明,来自条件性 STAT3 敲除小鼠的巨噬细胞在刺激同源 CTL 反应方面优于野生型巨噬细胞,并且能够在体外将肿瘤衍生抗原交叉呈递给 CTL。与 STAT3 缺陷型 APC 共培养的 CTL 表现出更强的增殖反应,并产生更多的 IFN-γ和 TNF-α,所有这些都已被证明在肿瘤耐受的 CD8 T 细胞中减少。因此,靶向 STAT3 信号转导代表了一种有吸引力的策略,可以增强肿瘤宿主中的 CTL 反应。

相似文献

1
Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.
Immunol Lett. 2010 Jul 8;131(2):126-30. doi: 10.1016/j.imlet.2010.03.004. Epub 2010 Mar 25.
8
Modulation of CD8+ T cell response to antigen by the levels of self MHC class I.
J Immunol. 2001 May 1;166(9):5416-21. doi: 10.4049/jimmunol.166.9.5416.

引用本文的文献

1
Unraveling the role of STAT3 in Cancer Cachexia: pathogenic mechanisms and therapeutic opportunities.
Front Endocrinol (Lausanne). 2025 Jul 9;16:1608612. doi: 10.3389/fendo.2025.1608612. eCollection 2025.
3
Antigen Cross-Presentation by Macrophages.
Front Immunol. 2020 Jul 8;11:1276. doi: 10.3389/fimmu.2020.01276. eCollection 2020.
4
STAT3, a Master Regulator of Anti-Tumor Immune Response.
Cancers (Basel). 2019 Aug 30;11(9):1280. doi: 10.3390/cancers11091280.
5
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.
Front Oncol. 2015 Jul 6;5:153. doi: 10.3389/fonc.2015.00153. eCollection 2015.
6
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cancer Res. 2014 Dec 15;74(24):7250-9. doi: 10.1158/0008-5472.CAN-13-3583. Epub 2014 Nov 6.
7
CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation.
Eur J Immunol. 2015 Jan;45(1):71-81. doi: 10.1002/eji.201444467. Epub 2014 Nov 10.
8
Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles).
J Immunother. 2014 Oct;37(8):383-93. doi: 10.1097/CJI.0000000000000051.
10
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2.

本文引用的文献

1
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.
Cancer Res. 2009 Apr 1;69(7):3086-94. doi: 10.1158/0008-5472.CAN-08-2826. Epub 2009 Mar 17.
2
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8. doi: 10.1073/pnas.0805599105. Epub 2008 Aug 22.
3
Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Cancer Res. 2008 Apr 15;68(8):2993-3000. doi: 10.1158/0008-5472.CAN-07-5008.
6
Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 2007;25:267-96. doi: 10.1146/annurev.immunol.25.022106.141609.
7
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response.
J Leukoc Biol. 2006 Apr;79(4):652-62. doi: 10.1189/jlb.1105628. Epub 2006 Jan 13.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验